Robert A.B. van Waterschoot

1.4k total citations
20 papers, 1.2k citations indexed

About

Robert A.B. van Waterschoot is a scholar working on Oncology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Robert A.B. van Waterschoot has authored 20 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Pharmacology and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Robert A.B. van Waterschoot's work include Drug Transport and Resistance Mechanisms (17 papers), Pharmacogenetics and Drug Metabolism (13 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Robert A.B. van Waterschoot is often cited by papers focused on Drug Transport and Resistance Mechanisms (17 papers), Pharmacogenetics and Drug Metabolism (13 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Robert A.B. van Waterschoot collaborates with scholars based in Netherlands, Switzerland and United States. Robert A.B. van Waterschoot's co-authors include Alfred H. Schinkel, Jos H. Beijnen, Els Wagenaar, Jurjen S. Lagas, Antonius E. van Herwaarden, Rolf W. Sparidans, Hilde Rosing, Cornelia M.M. van der Kruijssen, Rogier W. Rooswinkel and Olaf van Tellingen and has published in prestigious journals such as Journal of Clinical Investigation, Nature Reviews Drug Discovery and Cancer Research.

In The Last Decade

Robert A.B. van Waterschoot

20 papers receiving 1.1k citations

Peers

Robert A.B. van Waterschoot

ONCOL

PHARM

PPCH

GENET

Cindy Q. Xia United States

Nicola F. Smith United States

Cornelia M.M. van der Kruijssen Netherlands

Pauline Breedveld Netherlands

Sang Seop Lee South Korea

Kathleen Köck United States

Manfred G. Ismair Switzerland

Mayumi Saeki Japan

Amanda Obaidat United States

Sumathy Mathialagan United States

Cindy Q. Xia United States

Robert A.B. van Waterschoot

777 ×1.1

ONCOL

281 ×0.7

PHARM

481 ×1.4

307 ×1.3

PPCH

65 ×0.8

GENET

Citations per year, relative to Robert A.B. van Waterschoot Robert A.B. van Waterschoot (= 1×) peers Cindy Q. Xia

Countries citing papers authored by Robert A.B. van Waterschoot

Since Specialization

Citations

This map shows the geographic impact of Robert A.B. van Waterschoot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A.B. van Waterschoot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A.B. van Waterschoot more than expected).

Fields of papers citing papers by Robert A.B. van Waterschoot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A.B. van Waterschoot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A.B. van Waterschoot. The network helps show where Robert A.B. van Waterschoot may publish in the future.

Co-authorship network of co-authors of Robert A.B. van Waterschoot

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A.B. van Waterschoot. A scholar is included among the top collaborators of Robert A.B. van Waterschoot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A.B. van Waterschoot. Robert A.B. van Waterschoot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Dennis A., Robert A.B. van Waterschoot, Neil Parrott, et al.. (2018). Importance of target-mediated drug disposition for small molecules. Drug Discovery Today. 23(12). 2023–2030. 19 indexed citations

Waterschoot, Robert A.B. van, Neil Parrott, Andrés Olivares‐Morales, et al.. (2018). Impact of target interactions on small-molecule drug disposition: an overlooked area. Nature Reviews Drug Discovery. 17(4). 299–299. 20 indexed citations

Salphati, Laurent, Xiaoyan Chu, Liangfu Chen, et al.. (2014). Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins. Drug Metabolism and Disposition. 42(8). 1301–1313. 30 indexed citations

Lagas, Jurjen S., Carola W.N. Damen, Robert A.B. van Waterschoot, et al.. (2012). P-Glycoprotein, Multidrug-Resistance Associated Protein 2, Cyp3a, and Carboxylesterase Affect the Oral Availability and Metabolism of Vinorelbine. Molecular Pharmacology. 82(4). 636–644. 25 indexed citations

Koolen, Stijn L.W., Robert A.B. van Waterschoot, Olaf van Tellingen, et al.. (2011). From Mouse to Man: Predictions of Human Pharmacokinetics of Orally Administered Docetaxel From Preclinical Studies. The Journal of Clinical Pharmacology. 52(3). 370–380. 4 indexed citations

Waterschoot, Robert A.B. van & Alfred H. Schinkel. (2011). A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice. Pharmacological Reviews. 63(2). 390–410. 97 indexed citations

Lagas, Jurjen S., Robert A.B. van Waterschoot, Rolf W. Sparidans, et al.. (2010). Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation. Molecular Cancer Therapeutics. 9(2). 319–326. 151 indexed citations

Heine, Rob ter, Robert A.B. van Waterschoot, Ron J. Keizer, et al.. (2010). An Integrated Pharmacokinetic Model for the Influence of CYP3A4 Expression on the In Vivo Disposition of Lopinavir and Its Modulation by Ritonavir. Journal of Pharmaceutical Sciences. 100(6). 2508–2515. 15 indexed citations

Waterschoot, Robert A.B. van, Jurjen S. Lagas, Els Wagenaar, et al.. (2010). Individual and combined roles of CYP3A, P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. International Journal of Cancer. 127(12). 2959–2964. 44 indexed citations

10.

Waterschoot, Robert A.B. van, Els Wagenaar, Cornelia M.M. van der Kruijssen, et al.. (2009). ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity. Clinical Cancer Research. 15(24). 7616–7623. 13 indexed citations

11.

Waterschoot, Robert A.B. van, Jurjen S. Lagas, Els Wagenaar, et al.. (2009). Absence of Both Cytochrome P 450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity. Cancer Research. 69(23). 8996–9002. 85 indexed citations

12.

Herwaarden, Antonius E. van, Robert A.B. van Waterschoot, & Alfred H. Schinkel. (2009). How important is intestinal cytochrome P450 3A metabolism?. Trends in Pharmacological Sciences. 30(5). 223–227. 43 indexed citations

13.

Waterschoot, Robert A.B. van, Rogier W. Rooswinkel, Rolf W. Sparidans, et al.. (2009). Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam. Drug Metabolism and Disposition. 37(12). 2305–2313. 54 indexed citations

14.

Lagas, Jurjen S., Robert A.B. van Waterschoot, M. J. X. Hillebrand, et al.. (2009). Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment. Clinical Cancer Research. 15(7). 2344–2351. 140 indexed citations

15.

Zimmermann, Christian, et al.. (2008). PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. European Journal of Pharmaceutical Sciences. 36(4-5). 565–571. 29 indexed citations

16.

Lagas, Jurjen S., Rolf W. Sparidans, Robert A.B. van Waterschoot, et al.. (2008). P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin. Antimicrobial Agents and Chemotherapy. 52(3). 1034–1039. 52 indexed citations

17.

Waterschoot, Robert A.B. van, Rogier W. Rooswinkel, Els Wagenaar, et al.. (2008). Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. The FASEB Journal. 23(1). 224–231. 41 indexed citations

18.

Waterschoot, Robert A.B. van, Antonius E. van Herwaarden, Jurjen S. Lagas, et al.. (2007). Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes. Molecular Pharmacology. 73(3). 1029–1036. 97 indexed citations

19.

Herwaarden, Antonius E. van, Els Wagenaar, Cornelia M.M. van der Kruijssen, et al.. (2007). Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. Journal of Clinical Investigation. 117(11). 3583–3592. 189 indexed citations

20.

Waterschoot, Robert A.B. van, Peter H. J. Keizers, Chris de Graaf, Nico Vermeulen, & Richard A. Tschirret-Guth. (2006). Topological role of cytochrome P450 2D6 active site residues. Archives of Biochemistry and Biophysics. 447(1). 53–58. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact